WO2019231225A1 - 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 - Google Patents

안정한 아자시티딘-함유 약제학적 조성물의 제조방법 Download PDF

Info

Publication number
WO2019231225A1
WO2019231225A1 PCT/KR2019/006415 KR2019006415W WO2019231225A1 WO 2019231225 A1 WO2019231225 A1 WO 2019231225A1 KR 2019006415 W KR2019006415 W KR 2019006415W WO 2019231225 A1 WO2019231225 A1 WO 2019231225A1
Authority
WO
WIPO (PCT)
Prior art keywords
azacytidine
preparation
acetonitrile
solution
temperature
Prior art date
Application number
PCT/KR2019/006415
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
조중웅
김경해
이일웅
Original Assignee
주식회사 삼양바이오팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 삼양바이오팜 filed Critical 주식회사 삼양바이오팜
Priority to JP2020566917A priority Critical patent/JP7148642B2/ja
Publication of WO2019231225A1 publication Critical patent/WO2019231225A1/ko
Priority to JP2022152920A priority patent/JP2022185009A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PCT/KR2019/006415 2018-05-30 2019-05-29 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 WO2019231225A1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020566917A JP7148642B2 (ja) 2018-05-30 2019-05-29 安定したアザシチジン含有医薬組成物の製造方法
JP2022152920A JP2022185009A (ja) 2018-05-30 2022-09-26 安定したアザシチジン含有医薬組成物の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180061784A KR20190136284A (ko) 2018-05-30 2018-05-30 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
KR10-2018-0061784 2018-05-30

Publications (1)

Publication Number Publication Date
WO2019231225A1 true WO2019231225A1 (ko) 2019-12-05

Family

ID=68698347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/006415 WO2019231225A1 (ko) 2018-05-30 2019-05-29 안정한 아자시티딘-함유 약제학적 조성물의 제조방법

Country Status (3)

Country Link
JP (2) JP7148642B2 (ja)
KR (2) KR20190136284A (ja)
WO (1) WO2019231225A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
KR20130009909A (ko) * 2011-07-15 2013-01-24 보령제약 주식회사 아자시티딘의 전―동결건조 제제, 아자시티딘의 동결건조 제제 및 이의 제조방법
WO2013117969A1 (en) * 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
JP2014510755A (ja) * 2011-03-31 2014-05-01 セルジーン インターナショナル サルル ５−アザシチジンの合成
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
JP2014510755A (ja) * 2011-03-31 2014-05-01 セルジーン インターナショナル サルル ５−アザシチジンの合成
KR20130009909A (ko) * 2011-07-15 2013-01-24 보령제약 주식회사 아자시티딘의 전―동결건조 제제, 아자시티딘의 동결건조 제제 및 이의 제조방법
WO2013117969A1 (en) * 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Also Published As

Publication number Publication date
KR20190136284A (ko) 2019-12-10
JP2022500350A (ja) 2022-01-04
JP7148642B2 (ja) 2022-10-05
KR20210078462A (ko) 2021-06-28
JP2022185009A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
EP0246868B1 (en) Site specific alkylating agents
US9872873B2 (en) Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
KR20090114356A (ko) 뉴클레오시드 아릴 포스포르아미데이트 및 ｃ형 간염 바이러스의 치료를 위한 항바이러스제로서의 그 용도
WO2009107983A2 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
EP0649430B1 (en) Derivatives of 16-membered ring antibiotic macrolides
US6191143B1 (en) Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
EP3450450A1 (en) Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
WO2015102315A1 (ko) 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
KR20050084217A (ko) 무수 결정성 아지도 시토신 헤미설페이트 유도체
WO2019231225A1 (ko) 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
JPH01132597A (ja) ジデオキシシチジン誘導体
US6498238B1 (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
WO2019009661A1 (en) SKIN INJECTION COMPOSITION
WO1995002594A1 (en) Amide derivatives of 16-membered ring antibiotic macrolides
WO2014035064A1 (en) The novel tenofovir disoproxil salt and the preparation method thereof
WO2012008711A2 (en) Erlotinib dichloroacetate and anti-cancer agent comprising the same
AU2018375468B2 (en) Therapeutic agent for blood cancer
WO2011152657A2 (en) Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
WO2021020879A1 (en) Dinucleotide compounds for treating cancers and medical uses thereof
WO2016153304A1 (en) Preparation comprising indole compound and process for preparing the same
EP0676961A1 (en) Use of macrolides for the treatment of cerebral ischemia
WO2023163508A1 (ko) 향상된 용해도를 가지는 닥티노마이신 함유 약학조성물의 제조방법
WO2011013992A2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
EP1341412B1 (en) Indolocarbazole anticancer agents and methods of using them
WO2023128686A1 (ko) 삼중음성유방암의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19812383

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020566917

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19812383

Country of ref document: EP

Kind code of ref document: A1